focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 394.00
Bid: 393.00
Ask: 394.50
Change: 0.50 (0.13%)
Spread: 1.50 (0.382%)
Open: 390.00
High: 396.50
Low: 388.50
Prev. Close: 393.50
CHG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

4 Mar 2021 07:00

RNS Number : 0927R
Chemring Group PLC
04 March 2021
 

 

FOR IMMEDIATE RELEASE 4 MARCH 2021

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

AGM Update Announcement

Chemring issues the following update announcement, to coincide with the Company's Annual General Meeting taking place later today.

Current trading and outlook

Trading since the start of the current financial year has been as expected for both sectors. With the exception of the potential impact of foreign currency translation, discussed below, the Board's expectations for the current year remain unchanged.

Despite the ongoing restrictions of Covid-19, all our sites remain open and our people continue to show great professionalism and resilience. We continue to monitor our businesses and their supply chains closely.

With a robust strategy, market-leading positions across different geographies and sectors, and products and services that are critical to our government and commercial customers, Chemring's long-term prospects remain strong.

Foreign exchange

Foreign exchange rates continued to be volatile in the period and the average US$ rate of $1.37 compares to $1.28 in the first half of 2020, giving a 7% headwind. With approximately half of Group revenues US$ denominated, the US$ rate for the rest of 2021 may positively, or negatively, impact the translation of revenue, profit and cash flows. 2020 sensitivity analysis showed a 10c weakening of the US$ would negatively impact annual revenue by £13m and underlying operating profit by £2m.

Net debt

Net debt at 28 February 2021 was £51.0m (29 February 2020: £85.9m) as strong operating cash conversion continues to fund investment in capital expenditure. We continue to expect to make further progress on net debt in the full year.

Orders

Order intake in the period to 28 February 2021 was £128m (2020: £132m), with a book to bill ratio of 127% (2020: 125%). Having started the financial year with order cover of 78% our expected FY21 revenue is now 89% (2020: 88%) covered by revenue in the period and the order book, split 94% (2020: 92%) in Countermeasures & Energetics and 79% (2020: 80%) in Sensors & Information. The order book, which has been impacted by the weakening US dollar, stood at £481m at 28 February 2021 (2020: £478m).

In the Sensors & Information sector, our US sensors business received a further delivery order of $53m under the previously announced Husky Mounted Detection System $200m Indefinite Delivery / Indefinite Quantity ("IDIQ") contract. This provides excellent visibility on this Program of Record well into FY22.

In the Countermeasures & Energetics sector Chemring Countermeasures USA ("CCM USA") was awarded a 5-year IDIQ contract from the US Army for the manufacture of M206 and MJU-7A/B infrared decoy flares for the US Army and Air Force. We have received the first delivery order under this contract which is valued at $29m. Deliveries are expected to be made in FY21 and FY22 with all work being performed at CCM USA's facility in Toone, Tennessee.

Our niche energetics devices and propellant business in Scotland has signed a new long-term partnering agreement with Martin Baker Aircraft Company Ltd, the world leader in the design and manufacture of ejection and crashworthy seats. This 15 year agreement will see Chemring supply propellant material and pyro-mechanical devices for use in a wide range of Martin-Baker's ejection seats including those on the F-35 Joint Strike Fighter, and is valued at up to £160m.

Update on Tennessee expansion project

Investment in the expansion and automation of our Tennessee facility to meet the expected demand for F-35 countermeasures continues. Construction work of buildings has completed and the supply of complex manufacturing equipment to site continues, although some has been delayed due to suppliers being impacted by Covid-19. We still expect to generate incremental revenue from the new facility during the second half of our 2022 financial year.

Interim results date

The Group will report its interim results for the six months ended 30 April 2021 on 3 June 2021.

- ENDS -

 

For further information:

Rupert Pittman

Group Director of Corporate Affairs, Chemring Group PLC

+44 (0)1794 833901

Andrew Jaques

James Bavister

MHP Communications

+44 (0)20 3128 8170

 

Cautionary statement

This announcement contains unaudited information based on management accounts and forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements.

There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are; increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects.

Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

Notes to editors

· Chemring is a global business that specialises in the manufacture of advanced technology and high reliability products and the provision of critical services to the aerospace, defence and security markets

· Chemring is a business with an evolving purpose of innovating to protect and with that the Group is focused on protecting people, platforms, missions and information from constantly changing threats

· Employing approximately 2,300 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Countermeasures & Energetics, and Sensors & Information

· Operating in niche markets and with strong investment in research and development, Chemring has the agility to rapidly react to urgent customer needs

www.chemring.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMUOUBRAKUORAR
Date   Source Headline
14th Jul 202012:07 pmRNSSecond Price Monitoring Extn
14th Jul 202012:02 pmRNSPrice Monitoring Extension
10th Jul 202012:07 pmRNSSecond Price Monitoring Extn
10th Jul 202012:02 pmRNSPrice Monitoring Extension
8th Jul 202012:07 pmRNSSecond Price Monitoring Extn
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 20204:02 pmRNSHolding(s) in Company
6th Jul 20202:03 pmRNSHolding(s) in Company
6th Jul 20201:58 pmRNSHolding(s) in Company
2nd Jul 202012:02 pmRNSPrice Monitoring Extension
1st Jul 202011:36 amRNSTotal Voting Rights
22nd Jun 20204:26 pmRNSDirector/PDMR Shareholding
19th Jun 20209:34 amRNSBlock listing update
19th Jun 20209:28 amRNSBlock listing Interim Review
3rd Jun 20207:00 amRNSDirectorate Change
3rd Jun 20207:00 amRNSInterim Results
1st Jun 20209:20 amRNSTotal Voting Rights
27th May 202011:16 amRNSHolding(s) in Company
7th May 20207:00 amRNSCompletion of disposal
1st May 202011:39 amRNSTotal Voting Rights
29th Apr 202010:31 amRNSDisclosure of Rights Attached to Equity Shares
20th Apr 20207:05 amRNSDirector Declaration
14th Apr 20207:00 amRNSCovid-19 Update
7th Apr 202012:07 pmRNSSecond Price Monitoring Extn
7th Apr 202012:02 pmRNSPrice Monitoring Extension
3rd Apr 202012:34 pmRNSTotal Voting Rights
1st Apr 20201:36 pmRNSTotal Voting Rights
30th Mar 20204:09 pmRNSHolding(s) in Company
25th Mar 202012:57 pmRNSDirector/PDMR Shareholding
24th Mar 20202:18 pmRNSHolding(s) in Company
5th Mar 20204:01 pmRNSDoc re. Ordinary & Special Resolutions
4th Mar 20202:55 pmRNSResult of AGM
4th Mar 20207:00 amRNSAGM Trading Update
2nd Mar 202011:13 amRNSTotal Voting Rights
28th Feb 20201:32 pmRNSHolding(s) in Company
3rd Feb 202010:09 amRNSTotal Voting Rights
29th Jan 202012:16 pmRNSAdditional Listing
23rd Jan 20205:18 pmRNSDirector/PDMR Shareholding
21st Jan 202010:08 amRNSNotice of AGM
20th Jan 20204:40 pmRNSDirector/PDMR Shareholding
2nd Jan 20205:32 pmRNSTotal Voting Rights
23rd Dec 201910:50 amRNSHolding(s) in Company
18th Dec 201910:36 amRNSBlock listing Interim Review
17th Dec 20194:12 pmRNSHolding(s) in Company
17th Dec 20191:13 pmRNSDirector/PDMR Shareholding
17th Dec 20191:11 pmRNSDirector/PDMR Shareholding
17th Dec 20191:10 pmRNSDirector/PDMR Shareholding
17th Dec 20191:07 pmRNSDirector/PDMR Shareholding
17th Dec 20191:05 pmRNSDirector/PDMR Shareholding
17th Dec 20191:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.